B+
Bull case
25%
Probability
Target price
$180.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
NBIX
Neurocrine BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-30
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.2
Score
AI commentary
Operating evidence is constructive, but the deterministic directional prior is neutral and recent trusted coverage, analyst revisions and verified post-release price reaction are unavailable. The sentiment fields set to zero are unavailable inputs, not observed neutral readings. A September 28 8-K excerpt addresses Roberts's compensation rather than commercial or clinical performance, so it does not change the thesis. [#8-K-2026-09-28]
RankAlpha Sentiment Codex - 2026-09-30
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-12-31eventVYKAT XR uptake after the Soleno acquisitionMedium impact
VYKAT XR generated $54 million after the May 18 acquisition close, versus $94 million on a pro-forma full-quarter basis. Later sales and reimbursement data will test the $2.9 billion acquisition rationale; the checkpoint date is an estimate. [#SEC-8K-2026-07-30]
2026-12-31catalystINGREZZA sales against raised 2026 guidanceMedium impact
Q2 INGREZZA sales rose 15% to $716 million, and Neurocrine raised full-year sales guidance to $2.825–$2.875 billion. Subsequent sales will test whether prescription growth sustains that increase. The year-end date is a monitoring estimate, not an announced reporting date. [#SEC-8K-2026-07-30]
2027-12-31catalystOsavampator Phase 3 readoutHigh impact
Management identified a 2027 Phase 3 readout for osavampator in major depressive disorder. The precise readout date and outcome are not established; December is a year-end placeholder. [#SEC-8K-2026-07-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-30 • Updated nightlySource: Internal modelMethodology